Cargando…

Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)

Aims: Iron deficiency is common in patients with chronic kidney disease (CKD). Appropriate iron substitution is critical and intravenous iron is an established therapy for these patients. The objective of this study was to assess treatment routine, effectiveness, and safety of iron isomaltoside (Mon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Gert, Gøransson, Lasse G., Fernström, Anders, Furuland, Hans, Christensen, Jeppe H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dustri-Verlag Dr. Karl Feistle 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434427/ https://www.ncbi.nlm.nih.gov/pubmed/30614439 http://dx.doi.org/10.5414/CN109474

Ejemplares similares

The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency
por: Frigstad, Svein Oskar, et al.
Publicado: (2017)

NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease
por: Kalra, Philip A., et al.
Publicado: (2020)

A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO)
por: Mikhail, Ashraf I., et al.
Publicado: (2019)

Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy
por: Wesström, Jan
Publicado: (2020)

Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia
por: Kalra, Philip A, et al.
Publicado: (2016)

Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2018)

A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2017)

Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease
por: Nordfjeld, Kim, et al.
Publicado: (2012)

A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients
por: Bhandari, Sunil, et al.
Publicado: (2015)

A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000
por: Pollock, Richard F, et al.
Publicado: (2017)

A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial
por: Auerbach, Michael, et al.
Publicado: (2019)

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial
por: Markova, Veronika, et al.
Publicado: (2020)

Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience
por: Jesus-Silva, Jorge A., et al.
Publicado: (2020)

Introducing iron isomaltoside 1000 (Monofer®)—development rationale and clinical experience
por: Kalra, Philip A.
Publicado: (2011)

Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Pollock, Richard F., et al.
Publicado: (2019)

Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Aksan, Ayşegül, et al.
Publicado: (2019)

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
por: Kalra, Philip A., et al.
Publicado: (2016)

Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
por: Rostoker, Guy, et al.
Publicado: (2022)

Perioperative changes in haemoglobin and ferritin concentrations from preoperative intravenous iron isomaltoside for iron deficiency anaemia in patients with colorectal cancer: A pilot randomised controlled trial
por: Fung, Pui Lam Polly, et al.
Publicado: (2022)

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
por: Bhandari, Sunil, et al.
Publicado: (2020)

High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23
por: Dahlerup, Jens Frederik, et al.
Publicado: (2016)

A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial
por: Birgegård, Gunnar, et al.
Publicado: (2016)

Intravenous Iron Isomaltoside 1000 Reduces Postoperative Anemia in Patients Undergoing Elective Urologic Surgery and Those with Urosepsis
por: Goh, Hyeok Jun, et al.
Publicado: (2020)

A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
por: Reinisch, Walter, et al.
Publicado: (2013)

P1495: A PHASE III, RANDOMISED CONTROLLED SAFETY, EFFICACY AND COST EFFECTIVENESS TRIAL OF INTRAVENOUS IRON ISOMALTOSIDE (I3R) AND FERRIC CARBOXY MALTOSE (FERIUMR) IN SUBJECTS WITH IRON DEFICIENCY ANEMIA
por: Harikrishnan, P, et al.
Publicado: (2023)

A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000
por: Bhandari, Sunil
Publicado: (2011)

Iron Supplements for Infants at Risk for Iron Deficiency
por: MacQueen, Brianna C., et al.
Publicado: (2017)

Iron deficiency after kidney transplantation
por: Vinke, Joanna Sophia J, et al.
Publicado: (2020)

A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease
por: Reinisch, Walter, et al.
Publicado: (2015)

Iron deficiency and iron deficiency anemia in pregnancy
por: Malinowski, A. Kinga, et al.
Publicado: (2021)

Some Observations on Visits to the United States, Canada and Scandinavia
por: Learmonth, James
Publicado: (1950)

Role of NiMo Alloy and Ni Species in the Performance of NiMo/Alumina Catalysts for Hydrodeoxygenation of Stearic Acid: A Kinetic Study
por: Kumar, Pankaj, et al.
Publicado: (2019)

Oral versus intravenous iron therapy in iron deficiency anemia: An observational study
por: Das, Samarendra N., et al.
Publicado: (2020)

Associations between tryptophan and iron metabolism observed in individuals with and without iron deficiency
por: Wenninger, Julian, et al.
Publicado: (2019)

OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials
por: Wolf, Myles, et al.
Publicado: (2019)

Who's who in Scandinavia
por: Strute, Karl, et al.
Publicado: (1981)

Surgical Clinics in Scandinavia
por: Short, A. Rendle
Publicado: (1936)

Notes from Scandinavia
Publicado: (1889)

Estimating the relative importance of demic and cultural diffusion in the spread of the Neolithic in Scandinavia
por: Fort, Joaquim, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m5qggqd9m03t9p5ruq83rhfp95